SMB Technology Optimizing Purification

Atropisomers are axially chiral molecules resulting from restricted rotation around a single bond, typically between two sp²-hybridized atoms. Once overlooked in drug discovery, they are now gaining attention due to the potential for one isomer to exhibit significantly greater biological activity than its counterpart. Isolating the active isomer can enhance drug efficacy and specificity while minimizing off-target effects.

As the EU raises its environmental and social standards in the pharmaceutical sector, Latin American supply chains are feeling the ripple effects. Requirements such as mandatory Environmental Risk Assessments (ERAs) for medicinal products are increasingly influencing how LATAM companies operate—especially those exporting to or supplying the EU market. However, this evolving landscape also raises concerns over regulatory asymmetries. European pharmaceutical companies operating in LATAM may face higher compliance costs due to internal EU obligations, while competing with local firms not subject to equivalent environmental or social standards—potentially creating conditions of unfair competition. This panel will explore how EU-led sustainability initiatives impact trade dynamics in LATAM, and how multilateral cooperation, regulatory convergence, and the sustainability chapters of trade agreements can help level the playing field. Panellists will examine strategies for aligning standards while fostering innovation, resilience, and responsible growth across the LATAM–EU pharmaceutical value chain.

Expansion leverages proprietary chromatography expertise to overcome purification bottlenecks and secure domestic API manufacturing capacity.

CPHI Frankfurt, to be held at Messe Frankfurt from October 28–⁠30, 2025, will once again bring the pharmaceutical industry together for 3 days of collaboration and innovation. Our Track Sponsor interview series sits down with some of our conference track sponsors to discuss key themes and trends impacting the industry.

The pharmaceutical industry is pursuing sustainability and carbon neutrality with ambitious goals. Supported by groups like the Green Chemistry Roundtable (ACS), innovators and CDMOs are exploring technologies such as continuous flow, enzymatic reactions, and photochemistry. However, modifying commercial processes is often impractical due to regulatory hurdles. Since API manufacturing is solvent-intensive and waste-generating, alternative strategies are needed. Recovery and re-use technologies can reduce solvent volumes in transit and minimize waste disposal, all at relatively low energy cost. This presentation explores scalable separation technologies suitable for commercial-scale recovery and re-use of key solvents, reducing process mass intensity (PMI) and carbon footprint.

European hospitals face mounting pressures from staff shortages and sustainability demands, requiring medical devices that integrate into workflows while reducing environmental impact. In this context, adoption of new technologies depends on alignment with clinical, procurement, and sustainability priorities, as well as hospital processes. Drawing on interviews with key stakeholders in Poland and Switzerland, this session explores how a new packaging solution addresses these needs. The session then presents the Secure Blister-Free Syringe (SBFS), a solution co-developed by Alliance to Zero members to enhance sustainability and product safety in pharmaceutical packaging. The SBFS integrates a syringe with a label-friendly closure, a sealing functional label, and carton packaging—each designed by different partners to function as a unified system. By replicating the protective functions of plastic blisters used in 95% of prefilled syringes, the SBFS eliminates this component, significantly reducing packaging waste, volume, and logistics costs while supporting safer, greener hospital workflows.

As environmental and social responsibility gains prominence in EU trade policy, Latin America’s pharmaceutical sector is experiencing significant shifts. This session will offer a market overview of evolving trade patterns, highlighting how new EU requirements—such as Environmental Risk Assessments (ERAs)—are impacting LATAM exporters and suppliers.

This panel will explore how Artificial Intelligence is poised to revolutionise the pharmaceutical industry's sustainability efforts. We'll delve into the tangible benefits AI offers, from ecodesign to reporting, while critically examining the potential drawbacks, ethical dilemmas, and unintended consequences that must be navigated. The discussion will be a balanced look at AI as a powerful tool that requires careful management to ensure it genuinely drives a more sustainable future.

As the imperative for the adoption of sustainable practices intensifies, the performance of Lifecycle Assessments (LCA) emerges as a pivotal and strategic imperative within the pharmaceutical industry. This presentation seeks to provide a nuanced and comprehensive exploration of the dynamic domain of automated Lifecycle Assessments, offering a rigorous analysis of the methodology, advantages, challenges, and a prospective insight into future developments.

In the pursuit of business excellence, organizations must go beyond efficiency and cost to build operations that are sustainable, resilient, and future-ready. Supply chains are at the heart of this transformation. Join us on how we explore how integrating sustainability into supply chain strategies not only reduces risk, but also drives operational excellence, meets investor expectations, and strengthens brand trust. Participants will gain actionable insights into the five essential elements that build supply chain excellence through resilience and sustainability. Proactively Managing Supply Chain Risk Identifying and Addressing Vulnerabilities Aligning with Investor and Stakeholder Expectations Embedding Resilience as a Core Competency Driving Continuous Improvement and Strategic Action.

In the complex and highly regulated pharmaceutical and healthcare sectors, the ability to anticipate, withstand, respond to, and recover from disruptions is critical. This webinar will explore the fundamentals and strategic value of Business Continuity Management (BCM), with a particular focus on its alignment with supply chain risk management. Attendees will gain insights into how BCM can be effectively integrated with incident and risk management systems to build resilience across operations. We’ll explore best practices for implementing a holistic, coordinated approach that ensures continuity in the face of global supply chain volatility, regulatory pressures, and emerging threats such as cyberattacks and natural disasters.

This session will examine how companies can move beyond reactive compliance with CSRD and CSDDD regulations to create meaningful sustainability integration. As these frameworks take hold, the real challenge lies not just in meeting requirements but in embedding sustainability into strategy, governance, and risk management. The panel will explore common pitfalls companies encounter when developing reports, particularly when relying solely on internal approaches, and will clarify essential concepts including double materiality, value chain risks, and stakeholder expectations under these new regulations. Participants will learn how transparency and early alignment with CSRD and CSDDD frameworks can enhance brand trust, investor confidence, and operational resilience. The discussion will feature lessons learned from early adopters who have successfully navigated complex reporting requirements while avoiding reputational risks, providing practical insights on what works, what doesn't, and what's coming next in sustainability compliance.

Life-saving medicines, such as antibiotics, are essential — but so is the way we produce them. In a time of climate crisis, antimicrobial resistance, and global inequality, the pharmaceutical industry must take a leadership role in building a more sustainable and resilient future. Join us for this session as we present a bold and hopeful vision for the future — one where antibiotics and other essential medicines are manufactured responsibly, equitably, and sustainably. We will share insights from Centrient Pharmaceuticals, a global business-to-business manufacturer of foundational medicines, on how the industry can evolve through strong environmental stewardship, responsible supply chains, community engagement, and transparent governance. Discover how we are turning ambition into action by embedding ESG at the core of our business - integrating it across functions, culture and decision-making processes. This session goes beyond discussion — it is a collective invitation to help shape a pharmaceutical ecosystem that is cleaner, fairer, and ready for the future.

This session will address one of the pharmaceutical sector's greatest sustainability challenges: tackling Scope 3 emissions, which are the indirect emissions occurring throughout a company's value chain. Since no single company can achieve net-zero targets independently, the panel will explore how cross-industry collaboration, data transparency, and strategic technology partnerships are driving real progress in pharma sustainability. The discussion will cover how companies are overcoming barriers to sharing Scope 3 emissions data with suppliers and partners, along with effective strategies for aligning suppliers on decarbonization goals and reporting standards. The session will also spotlight innovative tools like Manufacture 2030 and examine how they enable scalable, verified emissions tracking and reduction efforts across the industry.

In today's volatile global environment, maintaining sustainability commitments is not just an ethical choice—it's a strategic necessity for pharmaceutical sector resilience. Rather than viewing sustainability as a secondary initiative, successful organizations recognize it as a cornerstone of trust, competitive advantage, and long-term success.
Strong sustainability practices strengthen organizational resilience through: Enhanced crisis management capabilities Improved stakeholder alignment and trust Clear, values-driven strategic direction Despite global political shifts and reduced international cooperation, companies that maintain transparent sustainability commitments while effectively communicating their values-based approach are better positioned to navigate market uncertainties and emerge as industry leaders.

SK pharmteco presents itself as a leading global CDMO specializing in small molecule APIs, intermediates, and raw starting materials (RSMs). The brochure emphasizes the company’s ability to solve complex challenges across the drug development lifecycle, from process development to CGMP manufacturing, analytical testing, and regulatory support

In our vast world, every action, no matter how small, creates a lasting impact. Life is full of decisions. Some are simple, while others are complex and critical. The most important choices require thoughtful consideration. True partners go beyond the basics, offering not only products and services but also the quality, technical expertise, and capabilities you can trust.

SK pharmteco provides accurate, timely, and reliable analytical services to support the full lifecycle of small molecule drug development and manufacturing. Services align with CGMP standards and global regulatory requirements (FDA, PMDA, EU QP). With expertise across 650+ APIs and drug products, SK pharmteco ensures confidence, compliance, and efficiency at every stage.